PRX 167700Alternative Names: PRO VAP-1 inh; PRX 167700H; PRX167700
Latest Information Update: 27 Sep 2016
At a glance
- Originator Cambridge Biotechnology
- Developer Proximagen
- Class Anti-inflammatories; Small molecules
- Mechanism of Action AOC3 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Inflammatory pain